Related Experiment Video
Updated: Jun 26, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Quality of Life in CAR-T Cell Therapy.
Caterina Alati1, Martina Pitea1, Gaetana Porto1
1Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", 89133 Reggio Calabria, Italy.
Chimeric antigen receptor T-cell (CAR-T) therapy significantly improves quality of life (QoL) for patients with blood cancers within three months. This rapid QoL recovery surpasses traditional treatments, offering a better patient experience.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough treatment for relapsed or refractory hematologic malignancies.
- High response rates are observed in B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma.
- Quality of life (QoL) is a critical factor in CAR-T therapy decision-making and patient care.
Purpose of the Study:
- To review current evidence on QoL outcomes for CAR-T therapy recipients.
- To understand the acute effects and recovery patterns of QoL post-CAR-T.
- To compare QoL changes with conventional therapies and identify optimization strategies.
Main Methods:
- Systematic literature review of studies reporting QoL in CAR-T therapy.
- Analysis of QoL metrics, including acute toxicity and long-term recovery.
- Comparative analysis against traditional treatment modalities.
Main Results:
- Most patients experience QoL recovery within 3 months of CAR-T therapy.
- This QoL improvement is often more rapid than with conventional treatments.
- Understanding QoL trajectories is crucial for patient-centered care.
Conclusions:
- CAR-T therapy offers significant QoL benefits for patients with hematologic malignancies.
- Early QoL recovery is a key advantage of CAR-T over other therapies.
- Further research should focus on optimizing QoL during and after CAR-T treatment.
